Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre.

Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre. Abstract Text:

R Roylance,B Seddon,A McTiernan,K Sykes,S Daniels,J Whelan,R Roylance,B Seddon,A McTiernan,K Sykes,S Daniels,J Whelan,

AIMS: Trabectedin (ET-743, Yondelis) is a marine-derived alkaloid that has two actions. It binds in the minor groove of DNA resulting in a conformational change; thus potentially altering interactions with transcription factors and other DNA binding proteins and it also interacts with the transcription-coupled nucleotide excision repair machinery to induce lethal double-stranded DNA breaks. In recent phase II trials it has shown considerable activity in the treatment of sarcomas. Here the use of trabectedin in patients with advanced refractory sarcoma from a single institution is presented. MATERIALS AND METHODS: Twenty-one patients with advanced refractory sarcoma from a single UK centre were treated with trabectedin on a named patient compassionate basis programme. All patients had received prior treatment with an anthracycline, and 95% had received ifosfamide. RESULTS: The patients received a median of four cycles of treatment. Objective partial responses were seen in three patients (14%) and a further eight patients (38%) achieved durable stable disease for a median duration of 4.5 months. The estimated 3- and 6-month progression-free survival was 58.8 and 17.6%, respectively. Six patients experienced early disease progression, and four patients died while on treatment. One death was due to treatment-related toxicity. Overall the drug was relatively well tolerated, with hepatic and haematological toxicities most commonly encountered. Both necessitated delays and/or dose reductions in a proportion of patients. Other significant toxicities were nausea, vomiting and asthenia. CONCLUSION: The disease responses and durable nature of disease stabilisation seen in a proportion of our patients support the continued investigational use of this drug in the treatment of advanced soft tissue sarcomas.

Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre. Publishing Authors By Initials

R Roylance,B Seddon,A McTiernan,K Sykes,S Daniels,J Whelan,R Roylance,B Seddon,A McTiernan,K Sykes,S Daniels,J Whelan,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Clinical oncology (Royal College of Radiologists (

VOLUME: 19

Page Numbers: 572-6

Journal Abbreviation:

ISSN: 0936-6555

DAY: 10

MONTH: 07

YEAR: 2007

Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9002902

Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre.

AFFILIATION: The London Bone and Soft Tissue Tumour Service, Department of Oncology, University College Hospital, London, UK.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Oncol (R Coll Radiol)

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Experience of the use of trabectedin ET-743, Yondelis in 21 patients with pre-treated advanced sarcoma from a single centre Related Publications

• 'No one agrees except for those of us who have it': endometriosis patients as an epistemological community.
• A conserved motif in region v of the large polymerase proteins of nonsegmented negative-sense RNA viruses that is essential for mRNA capping.
• A statistical approach for robust polyp detection in CT colonography.
• Automatic seed initialization for the expectation-maximization algorithm and its application in 3D medical imaging.
• Bladder cancer--contemporary dilemmas in its management.
• Computed tomographic changes of hypertensive encephalopathy.
• Description of a skin galvanometer that gives a graphic record of activity in the sympathetic nervous system.
• End products of the action of salivary alpha-amylase on amylose.
• Epidemiology of ulcerative colitis.
• Estimating resting energy expenditure in patients requiring nutritional support: a survey of dietetic practice.
• Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre.
• Functional definition of outer membrane proteins involved in preprotein import into mitochondria.
• Genome-Wide Analysis of mRNA Decay Rates and Their Determinants in Arabidopsis thaliana.
• HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab.
• Hydroa puerorum? urticaria pigmentosa.
• Improving Outcomes After Relapse in Ewing's Sarcoma: Analysis of 114 Patients From a Single Institution.
• ModuleFinder and CoReg: alternative tools for linking gene expression modules with promoter sequences motifs to uncover gene regulation mechanisms in plants.
• Mycosis fungoides.
• New approaches to phylogenetic tree search and their application to large numbers of protein alignments.
• Perioperative sargramostim (recombinant human GM-CSF) induces an increase in the level of soluble VEGFR1 in colon cancer patients undergoing minimally invasive surgery.
• Persistent elevation of plasma vascular endothelial growth factor levels during the first month after minimally invasive colorectal resection.
• Planning primary therapy.
• Proceedings: Glycogen and starch: specific events in their biosynthesis and metabolic regulation.
• Response to "Non-segmented negative-strand RNA virus RNA synthesis in vivo".
• Successful aspiration of an LAD thrombus 'cast' using an Export catheter.
• Sympathomimetic drugs in orthostatic hypotension.
• The Z-enzyme in amylolysis.
• The controversy regarding hand-assisted colorectal resection.
• The development and validation of a quality of life-measurement tool for patients with meniscal pathology: the Western Ontario Meniscal Evaluation Tool (WOMET).
• Vesicular stomatitis virus mRNA capping machinery requires specific cis-acting signals in the RNA.